We are a clinical stage antibody drug conjugate company that has leveraged twenty years of industry learnings to develop proprietary technologies that enable us to design antibody drug conjugates with improved efficacy, safety and tolerability relative to existing ADC therapies. Our proprietary technologies combined with our deep understanding of target and patient selection allow us to create precisely targeted therapies with the potential to radically improve patient lives.
Mersana Therapeutics, Inc. – Value Analysis (NASDAQ:MRSN) : November 24, 2017 Fri, 24 Nov 2017 16:27:55 +0000 Categories: Fundamental Analysis Yahoo FinanceClick here to see latest analysis Capitalcube gives Mersana Therapeutics, Inc. a score of 75. Our analysis is based on comparing Mersana Therapeutics, Inc. with the following peers – Protagonist Therapeutics, Inc., Parallax Health Sciences Inc., Plandai Biotechnology, Inc. and Pieris Pharmaceuticals, Inc. (PTGX-US, PRLX-US, PLPL-US and PIRS-US). Investment Outlook Mersana Therapeutics, Inc. has a ... Read more
(Read more...)
Mersana Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : MRSN-US : November 22, 2017 Wed, 22 Nov 2017 12:29:51 +0000 Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Mersana Therapeutics, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving Average Bullish ... Read more
(Read more...)
A requirement at this Cambridge biotech: Must love dogs Wed, 01 Nov 2017 20:10:11 +0000 Mersana Therapeutics has accomplished a lot in recent years. The Cambridge biotech signed collaboration deals with drug giants Takeda and Merck KGaA, released promising data on its experimental cancer treatments, and recently raised $75 million in an initial public offering. The company’s chief business officer, Eva Jack, participates in Canine Companions for Independence, a nonprofit program in which volunteer “puppy raisers” like her provide homes for aspiring service dogs before they are placed with children, adults and veterans with disabilities.
Mersana Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : MRSN-US : October 16, 2017 Mon, 16 Oct 2017 12:34:08 +0000 Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Mersana Therapeutics, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving Average Bullish ... Read more
(Read more...)
Boston biotech developing obesity drug pulls down $120M in IPO Thu, 05 Oct 2017 10:40:14 +0000 A 9-year-old biotech company headquartered in Boston’s Back Bay, Rhythm Pharmaceuticals Inc. has become the fourth local drugmaker to go public this year, raising $120 million in an upsized public offering. Rhythm, which has 15 employees based in a 6,830-square-foot office at 500 Boylston St., sold 7 million shares for $17 each, beating the range it floated in a federal filing just a couple weeks ago of $14-$16. It’s the second-biggest IPO for a Boston-area biotech in what’s so far a slow year, with only Cambridge-based Akcea Therapeutics (AKCA) raising more, with a $144 million IPO in July .
Mersana Therapeutics, Inc. – Value Analysis (NASDAQ:MRSN) : September 21, 2017 Thu, 21 Sep 2017 22:42:46 +0000 Categories: Fundamental Analysis Yahoo FinanceClick here to see latest analysis Capitalcube gives Mersana Therapeutics, Inc. a score of 69. Our analysis is based on comparing Mersana Therapeutics, Inc. with the following peers – Pieris Pharmaceuticals, Inc., PDL BioPharma, Inc., Bioblast Pharma Ltd. and InVivo Therapeutics Corporation (PIRS-US, PDLI-US, ORPN-US and NVIV-US). Investment Outlook Mersana Therapeutics, Inc. has a fundamental ... Read more
(Read more...)
Mersana Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : MRSN-US : September 20, 2017 Wed, 20 Sep 2017 13:57:26 +0000 Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Mersana Therapeutics, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving Average Bullish ... Read more
(Read more...)
Mersana Appoints Lawrence M. Alleva to Board of Directors Tue, 05 Sep 2017 20:05:00 +0000 CAMBRIDGE, Mass., Sept. 05, 2017-- Mersana Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody drug conjugates based on its pro
*Winners defined as our Top Picks that increased 20% or more within a 6-month period.
Red Letters imply that that particular criteria did not meet minimum requirements, e.g., a low GSA Rank would show it in red.
___ Red Line On Graph Shows a Trailing Stop Loss Based on Support and Resistance Levels. See how it works.
___ Blue Line On Graph Shows the 10-Week Moving Average.
___ Magenta Line On Graph Shows the 40-Week Moving Average.
Disclaimer The stock selections in our stock investing and stock trading database are not stock recommendations, but simply represent applications of a stock investing process. All materials, including our Top Stock Picks, are provided for information purposes only and should not be used or construed as an offer to sell, a solicitation of an offer to buy, or a recommendation for any security. Growth Stock Analytics, LLC is not responsible for gains/losses that may result in investing or trading in these securities. All information is believed to be obtained from reliable sources, but there is no guarantee that the information supplied is accurate, complete or timely. There is no guarantee or warranty with regard to the results obtained from its use. There is no guarantee of suitability or potential value of any particular investment or information source. You acknowledge that your requests for this information are unsolicited and shall neither constitute nor be considered investment advice. Past investing performance is not an indication of future performance results. Investing and trading in stocks is risky. Investors are encouraged to consult a registered stock broker or investment adviser before making any investing decisions. The interpretations and opinions expressed herein are solely those of Growth Stock Analytics, LLC, and not of any other individual or organization.
Accum/Dist: 0.51 (median winner: 1.53)
Above 40wkMA: 122% (median winner: 35%)
Disclaimer The stock selections in our stock investing and stock trading database are not stock recommendations, but simply represent applications of a stock investing process. All materials, including our Top Stock Picks, are provided for information purposes only and should not be used or construed as an offer to sell, a solicitation of an offer to buy, or a recommendation for any security. Growth Stock Analytics, LLC is not responsible for gains/losses that may result in investing or trading in these securities. All information is believed to be obtained from reliable sources, but there is no guarantee that the information supplied is accurate, complete or timely. There is no guarantee or warranty with regard to the results obtained from its use. There is no guarantee of suitability or potential value of any particular investment or information source. You acknowledge that your requests for this information are unsolicited and shall neither constitute nor be considered investment advice. Past investing performance is not an indication of future performance results. Investing and trading in stocks is risky. Investors are encouraged to consult a registered stock broker or investment adviser before making any investing decisions. The interpretations and opinions expressed herein are solely those of Growth Stock Analytics, LLC, and not of any other individual or organization.